Business
Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition
Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition.
About this update from Arno Therapeutics Inc
[{"type":"text","content":"\nFLEMINGTON, N.J., Sept. 19, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that an abstract outlining data supporting AR-12 as a novel anti-fungal drug has been accepted for presentation at the upcoming 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, being held October 25-29 in Orlando, FL.\n\n\tLead author, Avadhesh Kushwaha, at The University of Mississippi School of Pharmacy, University, MS, will provide information on AR-12's ability to penetrate the human nail, a necessary property for the treatment of onychomycosis, a common fungal infection of the nails.\n\n\tLogistical details for the poster presentation include:\n\n\t\n\t\t\n\t\t\t\n\t\t\t\tPoster R6046:\n\t\t\t\n\t\t\t\tTrans-ungual Delivery of AR-12, a Novel Antifungal Drug\n\t\t\n\t\t\n\t\t\t\n\t\t\t\tPresenting Author:\n\t\t\t\n\t\t\t\tAvadhesh Kushwaha\n\t\t\n\t\t\n\t\t\t\n\t\t\t\tDate, Time:\n\t\t\t\n\t\t\t\tThursday, October 29, 2015; 08:00 am – 11:30 a.m. EDT\n\t\t\n\t\t\n\t\t\t\n\t\t\t\tLocation:\n\t\t\t\n\t\t\t\tExhibit Hall WA3\n\t\t\n\t\n\n\n\tAbout AR-12\n\n\tAR-12 is an orally-available small molecule. Data reported previously demonstrate that the AR-12 mechanism of action may include induction of host cell autophagy and inhibit certain protein chaperones. Previously, AR-12 has completed Phase 1 clinical trials in patients with cancer. Additional pre-clinical research indicates that AR-12 may have potential as an antimicrobial agent in various infectious diseases. AR-12 has been granted two orphan drug designations in Europe for the treatment of cryptococcosis and tularaemia. In addition, Arno also has the rights to a broad portfolio of compounds in the \"AR-12 series\", which have been demonstrated to have a broad spectrum antimicrobial activity. In addition, the anti-viral activity of AR-12 and various analogues against Ebola and other pathogens of biodefense interest is being evaluated under a Cooperative Research and Development Agreement (CRADA) Material Transfer Agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID).\n\n\tAbout Arno Therapeutics\n\n\tArno Therapeutics is a clinical stage bioph...